Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

SMS Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,428,289

274 payments

Through program year 2025, SMS Clinical Research is reported as receiving $3,428,289 in research payments, across 274 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $704,523 103
2024 Research $1,078,518 93
2023 Research $440,105 30
2022 Research $1,126,250 26
2021 Research $22,973 13
2020 Research $33,405 4
2019 Research $22,515 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,751,168 164 payments
  2. Partner Therapeutics, Inc. $1,114,370 12 payments
  3. AstraZeneca UK Limited $220,464 2 payments
  4. Sanofi US Services Inc. $72,589 8 payments
  5. Tolmar, Inc. $53,900 36 payments
  6. Sun Pharmaceutical Industries Inc. $41,837 4 payments
  7. AstraZeneca Pharmaceuticals LP $37,953 5 payments
  8. Ionis Pharmaceuticals, Inc. $31,841 17 payments
  9. Romark Laboratories, LC $29,738 1 payment
  10. Insmed, Inc. $26,182 8 payments
Studies the money was for Research payments · program years 2019–2025
  1. Scope $1,114,370 12 payments
  2. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $514,802 28 payments
  3. A Phase 12 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $505,361 21 payments
  4. A Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccines Against Influenza in Healthy Adults $313,219 16 payments
  5. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $184,002 15 payments
  6. A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol $163,951 2 payments
  7. A Phase 3 Multicenter Parallelgroup Openlabel Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Herpes Zoster Subunit Vaccine in Adults 50 Years of Age $129,040 13 payments
  8. Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $72,589 8 payments
  9. Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) $66,542 1 payment
  10. An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $41,957 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record